Detalhe da pesquisa
1.
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Br J Clin Pharmacol
; 84(5): 876-887, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29346838
2.
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Br J Clin Pharmacol
; 79(5): 838-46, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377242
3.
Validation of 4ß-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Br J Clin Pharmacol
; 78(5): 1122-34, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24837659
4.
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Br J Clin Pharmacol
; 78(4): 877-85, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24697979
5.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Int J Clin Pharmacol Ther
; 52(7): 564-73, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24725442
6.
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Br J Clin Pharmacol
; 76(6): 908-16, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23488672
7.
Simultaneous oral therapeutic and intravenous ¹4C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.
Br J Clin Pharmacol
; 75(3): 763-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22823746
8.
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Br J Clin Pharmacol
; 75(2): 476-87, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22759198
9.
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 76(3): 432-44, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23210765
10.
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Br J Clin Pharmacol
; 76(5): 776-86, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23451769
11.
Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.
Clin Pharmacol Drug Dev
; 12(2): 159-167, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369799
12.
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.
Clin Pharmacol Drug Dev
; 12(5): 475-483, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36942508
13.
The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.
Pharmacoepidemiol Drug Saf
; 26(5): 603-605, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28444852
14.
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Clin Pharmacokinet
; 61(11): 1623-1639, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264536
15.
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
J Clin Pharmacol
; 62(8): 992-1005, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247274
16.
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis.
Chem Res Toxicol
; 24(9): 1575-85, 2011 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21728364
17.
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Br J Clin Pharmacol
; 72(1): 92-102, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21651615
18.
Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Clin Pharmacol Drug Dev
; 10(9): 974-984, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34342172
19.
Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan.
Clin Transl Sci
; 14(6): 2220-2230, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080309
20.
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
Clin Pharmacol Ther
; 109(5): 1314-1325, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33118153